diaDexus Raises Sixth Round

diaDexus Inc., a South San Francisco-based developer of a blood test for the prediction of cardiovascular disease, has raised around $9.2 million in Series F funding, according to a regulatory filing. Listed shareholders include Scale Venture Partners, GlaxoSmithKline and Baker Brothers Advisors.

The company previously raised around $170 million since 2000, from the above firms, Burrill & Co., Rho Ventures, Bain Capital’s Brookside Fund and Mosaix Ventures. This included a $40 million Series E round in late 2006. www.diadexus.com